33 results on '"Shenton, Geoff"'
Search Results
2. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
3. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts
4. Practice guideline: Preparation for CAR T‐cell therapy in children and young adults with B‐acute lymphoblastic leukaemia
5. CD3+TCRαβ/CD19+‐depleted stem cell boost and CD45RO+ memory T‐cell add‐back as a successful salvage treatment for poor graft function unresponsive to eltrombopag, following a second allogenic HSCT
6. Maintenance therapy for early loss of B-cell aplasia after CD19 CAR T-cell therapy
7. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy
8. Unusual relapse of low hypodiploid acute lymphoblastic leukaemia in a family with Li‐Fraumeni syndrome
9. Unusual Relapse of Low Hypodiploid Acute Lymphoblastic Leukaemia in a Family with Li-Fraumeni Syndrome
10. Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
11. Allogenic haematopoeitic stem cell transplant as cure for severe transfusion‐dependent non‐dominant hereditary spherocytosis due to homozygous SPTA1 mutation
12. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
13. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
14. Are trough tobramycin concentrations taken from a central venous catheter accurate enough to safely use?
15. UK experience of unrelated cord blood transplantation in paediatric patients
16. Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990–2002
17. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
18. The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study
19. Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial
20. Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme
21. RETINOBLASTOMA AND CLONING: POTENTIAL PITFALLS OF THE DIGITAL AGE: P.I.009
22. Allogenic haematopoeitic stem cell transplant as cure for severe transfusion‐dependent non‐dominant hereditary spherocytosis due to homozygous SPTA1 mutation.
23. Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study
24. Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
25. Delphi method to identify expert opinion to support children’s cancer referral guidelines
26. Delphi method to identify expert opinion to support children's cancer referral guidelines.
27. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS)
28. Prospective cohort study of procalcitonin levels in children with cancer presenting with febrile neutropenia
29. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts
30. Neuroacanthocytosis
31. Interleukin-6 and tumour necrosis factor alpha synergistically block S-phase cell cycle and upregulate intercellular adhesion molecule-1 expression on MCF7 breast carcinoma cells
32. Real‐world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
33. CD3 + TCRαβ/CD19 + -depleted stem cell boost and CD45RO + memory T-cell add-back as a successful salvage treatment for poor graft function unresponsive to eltrombopag, following a second allogenic HSCT.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.